PMGC Holdings (ELAB) Total Liabilities (2022 - 2026)
PMGC Holdings (ELAB) posted Total Liabilities of $13.4 million for Q1 2026, up 166.88% sequentially from $5.0 million in Q4 2025, and up 1666.07% YoY from $760268.0 in Q1 2025.
PMGC Holdings (ELAB) Total Liabilities (2022 - 2026) Analysis & Trends
PMGC Holdings has reported Total Liabilities for 5 years, with the latest figure at $13.4 million in Q1 2026.
- Quarterly Total Liabilities rose 1666.07% year-over-year to $13.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $13.4 million (up 1666.07% YoY) and the FY2025 annual result came in at $5.0 million, up 115.59% from the prior year.
- Total Liabilities rose to $13.4 million in Q1 2026 per ELAB's latest filing, from $5.0 million in the prior quarter.
- Over five years, Total Liabilities peaked at $1.7 billion in Q3 2023 and troughed at $326301.0 in Q2 2025.
- A 5-year average of $148.7 million and a median of $2.4 million in 2024 frame the typical range for Total Liabilities.
- The sharpest annual moves came in 2024 and 2026: Total Liabilities tumbled 99.85% in 2024, then soared 1666.07% in 2026.
- Over 5 years, Total Liabilities stood at $760873.0 in 2022, then surged by 79.12% to $1.4 million in 2023, then jumped by 71.23% to $2.3 million in 2024, then soared by 115.59% to $5.0 million in 2025, then surged by 166.88% to $13.4 million in 2026.
- According to Business Quant data, Total Liabilities over the past three periods registered $13.4 million, $5.0 million, and $6.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 4.20 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.35 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 10.03 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 3.22 Bn |
| 10 | PMGC Holdings | 3.01 Mn | -15.78 Mn | 385,691.00 | 19.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 13.43 Mn |
| Dec 31, 2025 | 5.03 Mn |
| Sep 30, 2025 | 6.45 Mn |
| Jun 30, 2025 | 326,301.00 |
| Mar 31, 2025 | 760,268.00 |
| Dec 31, 2024 | 2.33 Mn |
| Sep 30, 2024 | 2.65 Mn |
| Jun 30, 2024 | 2.44 Mn |
| Mar 31, 2024 | 1.74 Mn |
| Dec 31, 2023 | 1.36 Mn |
| Sep 30, 2023 | 1.75 Bn |
| Dec 31, 2022 | 760,873.00 |